Mesa Nilda, a director at United Therapeutics Corp (NASDAQ:UTHR), a biopharmaceutical company with impressive gross profit margins of 89% and an "Excellent" InvestingPro financial health rating, has sold shares of the company’s common stock, according to a recent SEC filing. The transaction, dated December 30, 2024, involved the sale of 255 shares at an average price of $355.77 each, totaling approximately $90,720. Following this sale, Nilda’s direct ownership stands at 5,528 shares. The stock has shown remarkable stability with a beta of 0.55 and has delivered a strong 62.6% return year-to-date. For deeper insights into insider transactions and 13 additional key metrics, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, United Therapeutics Corporation has been making waves with significant developments. The company recently announced the successful transplantation of a gene-edited pig kidney into a human patient, marking a major milestone in the field of xenotransplantation. This innovative procedure, performed under the FDA’s expanded access pathway, could potentially offer a solution to organ shortages.
Simultaneously, United Therapeutics has been making strides in the financial realm. The company reported robust third-quarter financial results, with revenues reaching $748.9 million, primarily driven by the strong performance of treprostinil-based products. However, not all products met projections, with Remodulin sales falling slightly short of expectations.
The company’s financial performance has caught the attention of analysts. H.C. Wainwright reaffirmed a Buy rating on the company and increased the price target to $425, citing strategic positioning and proactive measures. In contrast, Ladenburg Thalmann maintained a Neutral rating but raised the price target to $344.
In addition to these developments, United Therapeutics has completed a $1 billion accelerated share repurchase program. The company is also preparing for future clinical milestones, including the TETON 2 study results, and is awaiting a potential FDA decision on its Centralized Lung Evaluation System in 2025. These recent developments highlight United Therapeutics’ strategic focus on expanding commercial ventures and research and development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.